Between 2025 and 2030, the pharmaceutical industry faces its most dramatic patent cliff in history, with up to $300 billion in branded drug revenues exposed to generic competition. The upheaval will reshape healthcare economics, force strategic pivots at the world's largest drugmakers, and—if managed correctly—dramatically expand patient access to life-saving medicines.
The numbers are staggering. Johnson & Johnson's Stelara, which generated $10.9 billion in 2024 sales, is losing patent protection. So is Eli Lilly's Jardiance at $12.3 billion. Regeneron's Eylea at $9 billion. Novartis's Entresto at $7.8 billion. AstraZeneca's Farxiga at $7.7 billion. The list goes on.
